Sinotherapeutics (SH:688247) Shang Hai Zheng Quan Bao·2025-05-05 18:40Company Management Changes - JianSheng Wan, a non-independent director and core technical personnel, resigned due to age reasons and will no longer hold any position in the company [2][5][6] - Larry Yun Fang, the deputy general manager and core technical personnel, also resigned due to age but will continue to hold other positions within the company. He has been nominated as a candidate for a non-independent director [3][7][8] - MaoJian Gu, a non-independent director, will no longer participate in specific technical research but will retain other roles within the company [4][10] New Appointments - The company appointed Wu Yi Ming and Li Fang Li as deputy general managers, with Wu Yi Ming also taking on the role of financial officer [8][9] - The board approved the addition of Shen Qiang and Zhou Hai Feng as core technical personnel based on their qualifications and contributions to the company's development [14][16] Core Technical Personnel Adjustments - The adjustments in core technical personnel include the resignation of JianSheng Wan and Larry Yun Fang, who will no longer be recognized as core technical personnel [9][10] - MaoJian Gu will also be removed from the core technical personnel list but will continue in other capacities [10][17] Company’s R&D Capability - The company has established three major technology platforms and maintains a stable R&D team, with a focus on talent development and no significant risk of losing core technical personnel [16][17] - The company emphasizes the importance of its R&D management system and has sufficient backup personnel to ensure effective team operations [16][17] Compliance and Legal Matters - The company has ensured compliance with relevant regulations regarding the resignation and appointment of directors and senior management, with no reported violations of confidentiality or competition agreements [12][13][18]